INDIUM IN 111 CHLORIDE Drug Patent Profile

« Back to Dashboard

When do Indium In 111 Chloride patents expire, and when can generic versions of Indium In 111 Chloride launch?

Indium In 111 Chloride is a drug marketed by Curium and is included in one NDA.

The generic ingredient in INDIUM IN 111 CHLORIDE is indium in-111 chloride. There is one drug master file entry for this compound. Additional details are available on the indium in-111 chloride profile page.

Summary for INDIUM IN 111 CHLORIDE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	3
Patent Applications:	11
What excipients (inactive ingredients) are in INDIUM IN 111 CHLORIDE?	INDIUM IN 111 CHLORIDE excipients list
DailyMed Link:	INDIUM IN 111 CHLORIDE at DailyMed

US Patents and Regulatory Information for INDIUM IN 111 CHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Curium	INDIUM IN 111 CHLORIDE	indium in-111 chloride	INJECTABLE;INJECTION	019841-001	Sep 27, 1994		DISCN	Yes	No

Indium In-111 Chloride Market Dynamics and Financial Trajectory

Last updated: August 2, 2026

Indium In-111 chloride is a mature nuclear-medicine precursor used to radiolabel leukocytes, platelets, antibodies, peptides and other targeting molecules. Its commercial value comes from reliable isotope production, radiochemical quality, short-distance distribution and downstream radiopharmaceutical demand, not from conventional drug pricing or patent exclusivity. Revenue growth is likely to remain modest and specialized, with long-term pressure from gallium-68 and fluorine-18 alternatives.

What is Indium In-111 Chloride used for?

Indium In-111 chloride is a sterile injectable source of the radioactive isotope indium-111. It is generally used as a radiolabeling material rather than administered as an unmodified therapeutic or diagnostic agent.

Key technical characteristics include:

Attribute	Indium In-111 chloride
Active radionuclide	Indium-111
Physical half-life	Approximately 67.3 hours
Principal emissions	Gamma photons near 171 keV and 245 keV
Imaging platform	SPECT and planar nuclear imaging
Typical role	Precursor for radiolabeled cells, peptides, antibodies and proteins
Administration	Usually administered after radiolabeling a target compound
Commercial format	Sterile radioactive solution supplied in activity-calibrated vials
Supply constraint	Production, decay and time-sensitive transport
Primary customers	Hospitals, radiopharmacies, research centers and pharmaceutical developers

The relatively long half-life, compared with many other diagnostic radionuclides, permits delayed imaging over several days. That characteristic supports applications involving slow biological accumulation, including labeled leukocytes and certain peptide or antibody studies. The tradeoff is higher radiation exposure and lower imaging performance than many newer positron-emission tomography, or PET, agents.

How large is the Indium In-111 chloride market?

Indium In-111 chloride is a niche component of the broader radiopharmaceutical and nuclear-imaging market. Public companies generally do not report revenue for the chloride precursor as a separate product line. Financial analysis therefore requires separating three related revenue pools:

1. Sales of Indium In-111 chloride as a radiolabeling precursor.
2. Sales of finished In-111 radiopharmaceuticals.
3. Hospital and radiopharmacy services involving In-111-labeled cells or molecules.

The precursor market is materially smaller than the market for finished radiopharmaceuticals. A vial of Indium In-111 chloride has limited standalone clinical value unless a hospital or radiopharmacy has the equipment, validated process and licensed personnel needed to label a target compound.

Main demand sources

Demand is concentrated in:

• In-111-labeled autologous leukocyte imaging.
• In-111-labeled platelets and other cellular products.
• Research and clinical radiolabeling of antibodies and peptides.
• Legacy somatostatin-receptor imaging applications.
• Clinical trials involving targeted radionuclide delivery.
• Specialized nuclear-medicine centers without routine access to newer PET tracers.

Indium In-111-labeled leukocyte imaging remains relevant where clinicians need localization of infection or inflammation and where PET-based alternatives are unavailable, costly or operationally impractical.

What drives the financial trajectory of Indium In-111 chloride?

The financial trajectory is mature rather than high-growth. The product benefits from recurring clinical demand, but volumes are constrained by a declining or flat installed base of In-111 procedures and substitution by newer radiopharmaceuticals.

Revenue drivers

The main positive drivers are:

• Continued use of In-111-labeled leukocytes.
• Demand from hospitals that lack on-site PET radiopharmaceutical production.
• Growth in radiopharmacy outsourcing.
• Research use in antibody and peptide labeling.
• Expansion of nuclear-medicine services in emerging markets.
• Periodic supply shortages involving competing radionuclides.

Margin drivers

Profitability depends heavily on operations:

• Reactor or cyclotron production cost.
• Availability and price of enriched cadmium targets.
• Radiochemical purification yield.
• Batch size and activity concentration.
• Decay during manufacturing and transport.
• Product wastage from missed procedures.
• Regulatory compliance and radioactive-material handling.
• Air and ground transportation restrictions.
• Quality-control testing and release timing.

Unlike a conventional tablet, inventory cannot be held for long periods. Indium-111 loses activity continuously, and unsold inventory has declining economic value. Suppliers must coordinate production schedules, dose calibration, shipping and hospital appointments.

Financial trajectory by period

Period	Expected market condition	Financial implication
Near term	Stable but specialized demand; continued use in leukocyte and research applications	Revenue supported by recurring institutional orders
Medium term	Substitution by Ga-68 and F-18 imaging agents	Pressure on procedure volumes and pricing
Long term	Narrower role in delayed imaging, cell labeling and research	Lower volume, but potentially defensible specialty pricing

Public financial disclosures from major radiopharmaceutical suppliers typically combine In-111 products with broader nuclear-medicine portfolios. A reliable standalone revenue or market-share figure for Indium In-111 chloride is therefore not available from standard issuer reporting.

Who manufactures and distributes Indium In-111 chloride?

The relevant competitive field includes established nuclear-medicine suppliers, radiopharmacies and regional isotope producers. Major participants in the broader market have included Curium, Cardinal Health, Jubilant Radiopharma, NorthStar Medical Radioisotopes and other licensed regional manufacturers and distributors, depending on jurisdiction and product registration.

The competitive model is local and logistics-driven. A supplier with a technically equivalent product may not be a practical substitute if it cannot deliver calibrated activity within the required clinical window.

Competitive advantages

A supplier’s position depends on:

• Reliable isotope production.
• Consistent specific activity and radionuclidic purity.
• National or regional radioactive-material distribution licenses.
• Validated radiolabeling documentation.
• Hospital and radiopharmacy contracts.
• Ability to manage weather, transport and production disruptions.
• Integration with finished radiopharmaceutical services.

Manufacturing scale has value, but regional proximity can matter more than national branding because radioactive decay reduces usable activity during transit.

How does Indium In-111 chloride compare with Ga-68 and F-18 products?

Indium-111 competes indirectly with PET radionuclides, especially gallium-68 and fluorine-18. The competing products are usually finished radiopharmaceuticals rather than chemically identical chloride precursors.

Attribute	In-111	Ga-68	F-18
Imaging	SPECT	PET	PET
Half-life	67.3 hours	About 67.7 minutes	About 110 minutes
Image resolution	Lower than PET	Higher than SPECT	Higher than SPECT
Logistics	More flexible than short-lived PET isotopes	Requires rapid production and use	Requires cyclotron or nearby distribution
Delayed imaging	Strong advantage	Limited by decay	Limited by decay
Radiation burden	Generally higher for comparable diagnostic tasks	Often lower than In-111 protocols	Often favorable, depending on agent
Main commercial use	Specialized and legacy imaging	Modern targeted PET imaging	Broad PET imaging

Gallium-68 has displaced In-111 in several somatostatin-receptor imaging applications. Ga-68 DOTATATE and related agents provide PET resolution and quantitative imaging advantages over In-111 pentetreotide-type products. Fluorine-18 agents also compete for institutional imaging capacity and nuclear-medicine budgets.

In-111 retains an operational advantage when delayed imaging is clinically important or when a facility lacks access to PET production and distribution infrastructure.

What is the FDA regulatory status of Indium In-111 chloride?

Indium In-111 chloride is regulated as a prescription radioactive drug. Its manufacture and distribution require compliance with FDA drug requirements and applicable state or Nuclear Regulatory Commission radioactive-material controls.

The product’s regulatory profile is different from that of a conventional finished diagnostic drug:

• It is commonly used as a radiolabeling source.
• Its clinical value depends on the labeled product or cell preparation.
• Handling requires trained personnel and licensed facilities.
• Activity must be measured and documented at calibration time.
• Manufacturing controls must address sterility, radionuclidic identity, radionuclidic purity and radiochemical purity.

The FDA labeling framework identifies Indium In-111 chloride as a radioactive injectable intended for radiolabeling applications. Product-specific labeling, activity concentration and approved uses vary by manufacturer and jurisdiction [1].

Does Indium In-111 chloride have Orange Book exclusivity?

Indium In-111 chloride is not a conventional new molecular entity with meaningful remaining market exclusivity. Its commercial protection is primarily based on manufacturing controls, regulatory approvals, customer relationships, distribution capabilities and operational reliability.

The core isotope and basic chloride chemistry are longstanding. Any relevant intellectual-property rights are more likely to concern:

• Specific radiolabeling methods.
• Chelators and linker chemistry.
• Peptides, antibodies or cellular labeling protocols.
• Finished diagnostic compositions.
• Manufacturing and purification processes.
• Radiation-safety or dose-management systems.

The Orange Book status of a particular supplier product must be evaluated at the product and jurisdiction level. The commercial market does not appear to depend on a single active patent blocking generic or alternative production of the basic radionuclide salt.

What patents protect Indium In-111 chloride?

The basic Indium In-111 chloride product has limited patent-based defensibility. The isotope is a known radionuclide, and the underlying salt is a conventional chemical form. Patent value generally resides downstream.

Downstream patent categories

Relevant patent estates may cover:

• In-111-labeled peptides.
• In-111-labeled antibodies.
• Chelating agents such as DTPA, DOTA and related ligands.
• Methods for labeling leukocytes or platelets.
• Diagnostic use in infection, inflammation or tumor imaging.
• Kit configurations combining a targeting molecule with a radiolabeling reagent.
• Purification and quality-control methods.

Many older In-111 diagnostic-agent patents have expired or have limited commercial significance because clinical practice has shifted toward newer PET agents. Patent risk is therefore more relevant to a specific finished radiopharmaceutical than to Indium In-111 chloride itself.

Are there Paragraph IV challenges or generic entry risks?

A conventional Paragraph IV campaign is unlikely to be the primary competitive risk for Indium In-111 chloride. The more material risks are:

• New suppliers obtaining FDA approval.
• Hospital substitution between equivalent isotope sources.
• Radiopharmacy in-house production or compounding within applicable rules.
• Switching from In-111-labeled products to Ga-68 or F-18 products.
• Loss of contracts after supply interruptions.
• Reduced procedure volume from clinical guideline changes.
• Regional competition from lower-cost isotope producers.

For finished In-111 products, an abbreviated new drug application or other regulatory pathway may be relevant depending on dosage form, labeling, active ingredient characterization and FDA classification. For radiolabeled biologics or complex kits, the regulatory route may involve more extensive comparability and manufacturing documentation.

What manufacturing and intellectual-property barriers exist?

The strongest barriers are operational rather than patent-based.

Manufacturing barriers

Production requires:

• Access to an appropriate irradiation facility.
• Enriched target material.
• Chemical separation of indium from cadmium and other impurities.
• Control of radionuclidic purity.
• Sterile pharmaceutical manufacturing.
• Radioactive-material licensing.
• Calibrated activity measurement.
• Validated transport and storage procedures.

The short half-life increases the cost of quality failures. A batch that fails late-stage testing can create both direct product loss and downstream hospital disruptions.

Intellectual-property barriers

IP barriers are strongest when Indium-111 is incorporated into a proprietary diagnostic platform. Examples include:

• A patented peptide or antibody.
• A proprietary chelator.
• A specific diagnostic indication.
• A kit with protected formulation and labeling conditions.
• A finished product with regulatory exclusivity.

These rights do not necessarily prevent manufacture of Indium In-111 chloride. They can, however, restrict use of the isotope in a particular branded radiopharmaceutical.

What litigation and settlement agreements affect the product?

No major, widely recognized patent litigation campaign appears to define the standalone Indium In-111 chloride market. Litigation risk is more likely to arise in adjacent product categories involving:

• Proprietary radiolabeled peptides.
• Diagnostic antibodies.
• Radiopharmaceutical kits.
• Hospital compounding and reimbursement.
• Contract manufacturing and supply obligations.
• Regulatory approval of competing finished products.

Settlement agreements involving the basic chloride precursor would have limited strategic value unless they were tied to a specific downstream labeling technology or exclusive supply arrangement.

What geographic markets are most important?

North America and Europe have the most established regulatory and nuclear-medicine infrastructure. Japan and other advanced Asian markets also support specialist radiopharmaceutical use. Emerging markets have growth potential, but radioactive-material licensing, isotope access and distribution infrastructure limit adoption.

Geographic economics depend on:

• Reactor and cyclotron availability.
• Domestic radioactive-material regulation.
• Air-transport permissions.
• Hospital nuclear-medicine capacity.
• Radiopharmacy density.
• Reimbursement for SPECT procedures.
• Access to Ga-68 and F-18 alternatives.

Local production can be commercially attractive where import delays create excessive decay or where national regulations favor domestic radioisotope supply.

What generic launch scenarios exist?

Three launch scenarios are commercially realistic.

Scenario 1: Stable specialty market

Existing suppliers retain hospital contracts, and In-111 leukocyte labeling remains clinically established. Revenue is stable, with price increases offsetting limited volume erosion.

Scenario 2: Gradual substitution

Ga-68 and F-18 agents continue to replace In-111 in peptide and tumor imaging. Indium In-111 chloride becomes concentrated in leukocyte labeling, delayed imaging and research. Revenue declines gradually but does not disappear.

Scenario 3: Supply-led share capture

A new supplier gains market share through dependable delivery, competitive pricing or regional manufacturing. The product is chemically undifferentiated, so supply performance and customer service become the principal switching factors.

How strong is the commercial position of Indium In-111 chloride?

The product has moderate operational defensibility and weak standalone patent defensibility.

Factor	Assessment
Patent protection	Low for the basic chloride precursor
Regulatory barrier	Moderate to high
Manufacturing complexity	High
Customer switching cost	Moderate
Substitution risk	Moderate to high
Pricing power	Limited to moderate
Supply-chain sensitivity	High
Growth outlook	Flat to declining in routine imaging
Research upside	Moderate but uncertain
Bankruptcy or discontinuation risk	Low for established suppliers, higher for small regional producers

The market is likely to remain viable as a specialized radiopharmaceutical input. It is unlikely to become a major growth engine without a new high-volume clinical application.

Key Takeaways

• Indium In-111 chloride is primarily a radiolabeling precursor, not a conventional finished drug.
• Its half-life of about 67.3 hours supports delayed imaging and specialized cell-labeling procedures.
• The product has limited standalone patent protection and no clear blockbuster-style exclusivity.
• Revenue is driven by supply reliability, radiopharmacy contracts and hospital nuclear-medicine demand.
• Ga-68 and F-18 agents are the principal long-term substitution threats.
• The strongest barriers are isotope production, sterile manufacturing, licensing and time-sensitive distribution.
• Standalone product revenue is generally not disclosed by public companies.
• The most likely financial trajectory is stable-to-declining volume with specialty pricing and continued use in selected indications.
• Patent and litigation risk is concentrated in downstream labeled peptides, antibodies, kits and diagnostic methods.
• Generic entry risk is less important than regional manufacturing, contract retention and radiopharmaceutical substitution.

FAQs

Is Indium In-111 chloride a diagnostic drug or a manufacturing ingredient?

It is an FDA-regulated radioactive drug product used mainly as a radiolabeling precursor for diagnostic compounds, cells and biologic molecules.

Why is Indium-111 still used when PET isotopes are available?

Its 67.3-hour half-life permits delayed imaging and supports procedures involving slow biological localization. PET isotopes often provide better resolution but require faster production, transport and administration.

Does Indium In-111 chloride have blockbuster revenue potential?

No. Its market is specialized, and the precursor has limited standalone clinical value. Larger revenue opportunities exist in finished radiolabeled peptides, antibodies and cell-labeling services.

What is the main commercial risk for an Indium-111 supplier?

The main risk is substitution by Ga-68 or F-18 products, followed by supply-chain failures, loss of hospital contracts and declining use of legacy SPECT procedures.

Can a hospital replace one Indium In-111 chloride supplier with another?

Usually, substitution is feasible if the alternative product meets regulatory, quality and radiolabeling requirements. In practice, validated procedures, delivery timing, licensing and radiopharmacy contracts can delay switching.

References

1. U.S. Food and Drug Administration. (n.d.). Indium In 111 Chloride Injection prescribing information. FDA Drugs@FDA and product labeling database. https://www.accessdata.fda.gov/scripts/cder/daf/

2. International Atomic Energy Agency. (2019). Production of radionuclides in cyclotrons. IAEA. https://www.iaea.org/

3. International Atomic Energy Agency. (2015). Nuclear medicine resources manual. IAEA. https://www.iaea.org/

4. U.S. Nuclear Regulatory Commission. (n.d.). Medical use of byproduct material. NRC. https://www.nrc.gov/materials/miau/med-use.html

5. National Library of Medicine. (n.d.). Indium In-111 chloride: Drug information and labeling records. DailyMed. https://dailymed.nlm.nih.gov/